Effective vaccine against Rotavirus

In this week's Lancet The authors say: "Our findings confirm the high incidence of rotavirus gastroenteritis during the first two years of life and, hence, a need for long-term protection induced by rotavirus vaccination. The human rotavirus vaccine RIX4414 showed high and sustained efficacy against severe rotavirus gastroenteritis and admission for rotavirus gastroenteritis." They conclude: "Our study findings show that, if integrated into routine infant immunization schedules, vaccination with RIX4414 could result in significant reduction not only of rotavirus disease burden but also of severe paediatric gastroenteritis during the first two years of life."